Journal Article

Reduced expression of CYLD in human colon and hepatocellular carcinomas

Claus Hellerbrand, Elisabeth Bumes, Frauke Bataille, Wolfgang Dietmaier, Ramin Massoumi and Anja K. Bosserhoff

in Carcinogenesis

Volume 28, issue 1, pages 21-27
Published in print June 2006 | ISSN: 0143-3334
Published online January 2007 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/bgl081
Reduced expression of CYLD in human colon and hepatocellular carcinomas

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

CYLD was originally identified as a tumor suppressor that is mutated in familial cylindromatosis. Recent studies suggested a role for CYLD in nuclear factor-kappaB (NF-κB) regulation. NF-κB activation has been connected with multiple aspects of oncogenesis but the underlying molecular mechanisms of persistent NF-κB activation in tumors remain largely unknown. Thus, we evaluated CYLD transcription in different colon and hepatocellular carcinoma cell lines and tissue samples, respectively. CYLD was downregulated or lost in all tumor cell lines investigated as compared with primary human colonic epithelial cells and hepatocytes, respectively. Further, quantitative PCR analysis revealed reduced CYLD mRNA expression in most tumor samples compared with non-tumorous tissue. Analysis on protein level confirmed these findings. Functional assays with CYLD transfected cell lines revealed that CYLD expression decreased NF-κB activity. Thus, functional relevant loss of CYLD expression may contribute to tumor development and progression, and may provide a new target for therapeutic strategies.

Journal Article.  3949 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.